Patients who have heart attacks frequently progress to heart failure,
which has a five-year mortality of 40-50%1, which is more deadly
than cancer. The size of the heart attack (amount of damage or
infarct size) is the single most important factor in determining future
progression to heart failure.
RIC has been shown to reduce infarct size in multiple heart attack
trials, but how does that translate into heart failure reduction?